银屑病关节炎疗效阈值随基线疾病活动度变化,但与既往TNF抑制剂治疗无关
该研究事后汇总3项随机对照试验数据,在活动性银屑病关节炎患者中按既往TNF抑制剂治疗史及基线cDAPSA/PASDAS活动度分层,采用分布法确定MCII阈值。结果显示各指标MCII阈值在TNF抑制剂经治与初治者间一致,但高基线疾病活动度者cDAPSA的MCII更严格,PASDAS则无此差异;古塞奇尤单抗组自第8周起达到MCII的比值比优于安慰剂。
要点
- MCII阈值在TNF抑制剂经治与初治患者间保持一致。
- 高基线疾病活动度者cDAPSA的MCII阈值更严格,PASDAS无此差异。
- 古塞奇尤单抗自第8周起达到MCII的比值比优于安慰剂。
核心结论
- MCII阈值不受既往TNF抑制剂治疗影响,但高基线关节疾病活动度者阈值更高,提示疾病严重程度可能影响患者对改善的感知。
研究设计与样本
- 事后汇总分析3项随机对照试验,纳入活动性银屑病关节炎患者,接受古塞奇尤单抗每8周一次或安慰剂并于第24周转换至古塞奇尤单抗每8周一次。
主要发现
- 所有 examined 指标的估计MCII阈值在TNF抑制剂经治与生物制剂初治队列间一致。
- 高基线疾病活动度者的cDAPSA的MCII阈值较中等活动度者更严格,PASDAS无此差异。
- 古塞奇尤单抗治疗者自第8周起达到MCII阈值的比值比优于安慰剂,且不受既往TNF抑制剂及基线cDAPSA和PASDAS活动度影响。
关键数值与推荐
- 采用已建立的分布法确定cDAPSA、PASDAS及患者报告的关节炎、银屑病、疼痛、疲劳和身体功能评估的MCII阈值。
- 按既往TNF抑制剂治疗及基线cDAPSA和PASDAS疾病活动度(高 vs 中等)定义亚组。
临床怎么用
- 这些发现可能有助于在共享决策和达标治疗策略中设定更个性化的目标,并辅助解释随机对照试验结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Efficacy thresholds allow interpretation of randomised clinical trials (RCTs) and establishment of treatment targets. To assess the need for more personalised treatment goals, minimal clinically important improvement (MCII) thresholds in psoriatic arthritis (PsA) clinical and patient-reported outcome measures were determined by treatment history and baseline disease activity. METHODS: This post hoc analysis pooled data from 3 RCTs in participants with active PsA receiving guselkumab every 8 week (Q8W), or placebo with W24 transition to guselkumab Q8W. MCII thresholds for clinical Disease Activity Index for PsA (cDAPSA), PsA Disease Activity Score (PASDAS), and patient-reported assessments of arthritis and psoriasis, pain, fatigue, and physical function were determined using established distribution-based methods in participant subgroups defined by prior tumour necrosis factor inhibitor (TNFi) treatment and baseline cDAPSA and PASDAS disease activity (high vs moderate). RESULTS: In this pooled RCT population, estimated MCII thresholds for all examined measures were consistent across TNFi-experienced and biologic-naïve cohorts. However, the determined cDAPSA, but not PASDAS, MCII was more stringent among participants with high vs moderate baseline disease activity. Guselkumab-treated participants had greater odds of achieving MCII thresholds vs placebo as early as W8, irrespective of prior TNFi and baseline cDAPSA and PASDAS disease activity, supporting the known-groups validity of the estimated thresholds. CONCLUSIONS: Estimated MCII thresholds were consistent regardless of prior TNFi but greater for participants with higher baseline joint disease activity, indicating disease severity may impact perceived PsA improvement. These findings may aid in setting more personalised goals in shared decision‑making and treat-to-target strategies, and RCT interpretation.
引用
- Ogdie A, Mease PJ, Rampakakis E, et al. Thresholds for efficacy outcomes in psoriatic arthritis vary according to baseline disease activity but not according to prior tumour necrosis factor inhibitor treatment. Ann Rheum Dis. 2026. PMID: 42128704. doi:10.1016/j.ard.2026.03.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。